| 1 |
35447344 | The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. | 2022 Jul 1 |
2 |
| 2 |
35457272 | Revisiting the Role of Astrocytic MAOB in Parkinson's Disease. | 2022 Apr 18 |
3 |
| 3 |
35587267 | Antibody-Mediated Screening of Peptide Inhibitors for Monoamine Oxidase-B (MAO-B) from an Autodisplayed FV Library. | 2022 Jun 15 |
2 |
| 4 |
35624746 | Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease. | 2022 Apr 29 |
1 |
| 5 |
32086435 | C/EBPβ/δ-secretase signaling mediates Parkinson's disease pathogenesis via regulating transcription and proteolytic cleavage of α-synuclein and MAOB. | 2021 Feb |
1 |
| 6 |
32093545 | The conformational dynamics of wing gates Ile199 and Phe103 on the binding of dopamine and benzylamine substrates in human monoamine Oxidase B. | 2021 Mar |
4 |
| 7 |
33387637 | Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. | 2021 Mar |
1 |
| 8 |
33898820 | Binding mechanism of naringenin with monoamine oxidase - B enzyme: QM/MM and molecular dynamics perspective. | 2021 Apr |
2 |
| 9 |
33915673 | Factors Associated with Medication Beliefs in Patients with Parkinson's Disease: A Cross-Sectional Study. | 2021 May |
1 |
| 10 |
33960511 | Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease. | 2021 Sep |
1 |
| 11 |
34225162 | The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. | 2021 Sep |
1 |
| 12 |
34287249 | The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia. | 2021 Jul 8 |
3 |
| 13 |
34503991 | Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases. | 2021 Nov |
2 |
| 14 |
34533445 | Association of the MAOB rs1799836 Single Nucleotide Polymorphism and APOE ε4 Allele in Alzheimer's Disease. | 2021 |
2 |
| 15 |
34553601 | Identification of a Chlorogenic Ester as a Monoamine Oxidase (MAO-B) Inhibitor by Integrating "Traditional and Machine Learning" Virtual Screening and In Vitro as well as In Vivo Validation: A Lead against Neurodegenerative Disorders? | 2021 Oct 6 |
1 |
| 16 |
34970960 | The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update. | 2021 Dec 31 |
2 |
| 17 |
30127471 | Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. | 2020 Apr |
2 |
| 18 |
31562557 | Selegiline: a molecule with innovative potential. | 2020 May |
1 |
| 19 |
31686637 | Parkinson's Disease: A Review from Pathophysiology to Treatment. | 2020 |
2 |
| 20 |
31771069 | Relationships of Cerebrospinal Fluid Alzheimer's Disease Biomarkers and COMT, DBH, and MAOB Single Nucleotide Polymorphisms. | 2020 |
2 |
| 21 |
31836905 | Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease. | 2020 May |
1 |
| 22 |
32162782 | Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B. | 2020 May 6 |
1 |
| 23 |
32378642 | [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect®)]. | 2020 |
4 |
| 24 |
32408504 | Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. | 2020 May 12 |
2 |
| 25 |
32474182 | 3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter? | 2020 Aug |
2 |
| 26 |
32612042 | [Safinamide Mesilate (Equfina® TABLETS 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety]. | 2020 |
1 |
| 27 |
32621059 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. | 2020 Nov |
1 |
| 28 |
32711021 | Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine. | 2020 Oct |
2 |
| 29 |
32786232 | Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker. | 2020 Aug 24 |
1 |
| 30 |
32942081 | A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. | 2020 Nov 15 |
1 |
| 31 |
33008589 | Intracerebroventricular injection of L-arginine and D-arginine induces different effects under an acute stressful condition. | 2020 Dec 17 |
1 |
| 32 |
33081086 | Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics. | 2020 Oct 16 |
3 |
| 33 |
33210537 | Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. | 2020 Dec 10 |
4 |
| 34 |
30160213 | Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. | 2019 |
3 |
| 35 |
30386930 | Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. | 2019 Apr |
2 |
| 36 |
30599413 | The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone. | 2019 Apr |
2 |
| 37 |
30666491 | Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. | 2019 Nov |
1 |
| 38 |
30738894 | Regulation of Monoamine Oxidase B Gene Expression: Key Roles for Transcription Factors Sp1, Egr1 and CREB, and microRNAs miR-300 and miR-1224. | 2019 Mar 15 |
2 |
| 39 |
30963543 | Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. | 2019 Jul |
1 |
| 40 |
31017021 | Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status. | 2019 May |
1 |
| 41 |
31258092 | Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase. | 2019 |
1 |
| 42 |
31421966 | Rasagiline derivatives combined with histamine H3 receptor properties. | 2019 Oct 1 |
1 |
| 43 |
28460566 | Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity. | 2018 May |
3 |
| 44 |
29417334 | Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. | 2018 Nov |
2 |
| 45 |
29552556 | Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors. | 2018 |
3 |
| 46 |
29569037 | Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. | 2018 Nov |
4 |
| 47 |
29578580 | MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. | 2018 Jul |
3 |
| 48 |
29697034 | Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. | 2018 |
1 |
| 49 |
29956417 | Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. | 2018 Nov |
1 |
| 50 |
30077198 | Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease. | 2018 Aug |
3 |